Brain Insight Report for Drug Development

About Ceretype Neuromedicine

Ceretype Neuromedicine is a private, pre-revenue diagnostics and services company founded in 2021 and based in Cambridge, USA. It is tackling the critical lack of objective biomarkers in psychiatry and neurology by commercializing a next-generation fMRI analysis platform that provides reliable, actionable maps of brain circuit activity. The company's initial focus is on supporting drug development and, eventually, clinical practice for conditions like anxiety, mood disorders, and neurodegenerative diseases. Ceretype's value proposition lies in its ability to segment diseases biologically, measure treatment effects directly on neural circuits, and enable more precise clinical trials and patient care.

Therapeutic Areas